Tabang Biologic Group, founded in 2002, is a blood product and biopharmaceutical company. This financing round will further optimize the Group's capital structure and help it gain a firmer foothold in China's market.
Biomedical drop operation
Tabang Biologic Group(Chinese: 泰邦生物) harvested USD 300 million in a single financing round led by Platinum Orchid, a subsidiary of the Abu Dhabi Investment Authority (ADIA), and the Government of Singapore Investment Corporation (GIC). China Life Private Equity Investment(Chinese: 国寿股权) and Xinda Kunpeng(Chinese: 信达鲲鹏) also participate in the investment.
The Group was formerly listed on the NASDAQ under the ticker symbol of 'CBPO'. This round of financing is the first for Taibang since a consortium led by Centurium Capital(Chinese: 大钲资本) privatized the Group in April 2021.
The proceeds will provide extensive resources for Taibang in various aspects such as plasma station expansion, new product development, and growing its business in China's market.
The Group has a production base, an R&D team and a laboratory for blood products. Its product lines cover three categories of albumin, immunoglobulin and coagulation factors, and more than 20 kinds of blood products.
Besides blood products, Taibang has multiple product lines that make placenta polypeptide, artificial dura mater, artificial spinal dura mater, artificial nerve sheath tubes, etc. It also has a full line of products in neurosurgery under Zeppelin, a German brand. Its products cover most of the provincial markets in China's mainland.
Centurium Capital, first invested in TaiBang in 2018, is its largest institutional shareholder. Healthcare is one of its key investment areas.
The competitors of Taibang include Tiantan Bio(Chinese: 天坛生物), Hualan Bio(Chinese: 华兰生物), Shanghai Raas(Chinese: 上海莱士), Pailin Bio(Chinese: 派林生物).